VolitionRx Initiates Second Prostate Cancer Pilot Study Assessing Nucleosomics(R) Technology
Go back to VolitionRx Initiates Second Prostate Cancer Pilot Study Assessing Nucleosomics(R) Technology| VolitionRX Limited (NYSE: VNRX) | Delayed: 1.46 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.46 | 52 Week High | $5.86 | |||
| Open | $1.36 | 52 Week Low | $3.05 | |||
| Day High | $1.48 | P/E | N/A | |||
| Day Low | $1.36 | EPS | $-0.45 | |||
| Volume | 130,218 | |||||
| VolitionRX Limited (NYSE: VNRX) | Delayed: 1.46 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.46 | 52 Week High | $5.86 | |||
| Open | $1.36 | 52 Week Low | $3.05 | |||
| Day High | $1.48 | P/E | N/A | |||
| Day Low | $1.36 | EPS | $-0.45 | |||
| Volume | 130,218 | |||||

